187 related articles for article (PubMed ID: 37684173)
41. The control of adaptive immune responses by the innate immune system.
Schenten D; Medzhitov R
Adv Immunol; 2011; 109():87-124. PubMed ID: 21569913
[TBL] [Abstract][Full Text] [Related]
42. [Basic background for adjuvant immunotherapy].
Seya T
Nihon Rinsho; 2012 Dec; 70(12):2059-65. PubMed ID: 23259375
[TBL] [Abstract][Full Text] [Related]
43. Plant Phenolics and Lectins as Vaccine Adjuvants.
Reyna-Margarita HR; Irais CM; Mario-Alberto RG; Agustina RM; Luis-BenjamÃn SG; David PE
Curr Pharm Biotechnol; 2019; 20(15):1236-1243. PubMed ID: 31333121
[TBL] [Abstract][Full Text] [Related]
44. Toll or toll-free adjuvant path toward the optimal vaccine development.
Ishii KJ; Akira S
J Clin Immunol; 2007 Jul; 27(4):363-71. PubMed ID: 17370119
[TBL] [Abstract][Full Text] [Related]
45. Combinational PRR Agonists in Liposomal Adjuvant Enhances Immunogenicity and Protective Efficacy in a Tuberculosis Subunit Vaccine.
Hao L; Wu Y; Zhang Y; Zhou Z; Lei Q; Ullah N; Banga Ndzouboukou JL; Lin X; Fan X
Front Immunol; 2020; 11():575504. PubMed ID: 33117374
[TBL] [Abstract][Full Text] [Related]
46. Innate recognition of microbial-derived signals in immunity and inflammation.
Zhang Y; Liang C
Sci China Life Sci; 2016 Dec; 59(12):1210-1217. PubMed ID: 27888386
[TBL] [Abstract][Full Text] [Related]
47. Innate signaling by mycobacterial cell wall components and relevance for development of adjuvants for subunit vaccines.
Tima HG; Huygen K; Romano M
Expert Rev Vaccines; 2016 Nov; 15(11):1409-1420. PubMed ID: 27206681
[TBL] [Abstract][Full Text] [Related]
48. Editorial: Pattern recognition receptors at the crosstalk between innate and adaptive immune systems and implications for vaccine development.
Rossi O; Mastroeni P
Front Cell Infect Microbiol; 2022; 12():1088029. PubMed ID: 36530438
[No Abstract] [Full Text] [Related]
49. Selection of adjuvants for vaccines targeting specific pathogens.
Sarkar I; Garg R; van Drunen Littel-van den Hurk S
Expert Rev Vaccines; 2019 May; 18(5):505-521. PubMed ID: 31009255
[TBL] [Abstract][Full Text] [Related]
50. Epigenetic adjuvants: durable reprogramming of the innate immune system with adjuvants.
Lee A; Wimmers F; Pulendran B
Curr Opin Immunol; 2022 Aug; 77():102189. PubMed ID: 35588691
[TBL] [Abstract][Full Text] [Related]
51. [Vaccine adjuvant].
Aoshi T; Ishii KJ
Nihon Rinsho; 2011 Sep; 69(9):1547-53. PubMed ID: 21922751
[TBL] [Abstract][Full Text] [Related]
52. Emerging concepts in the science of vaccine adjuvants.
Pulendran B; S Arunachalam P; O'Hagan DT
Nat Rev Drug Discov; 2021 Jun; 20(6):454-475. PubMed ID: 33824489
[TBL] [Abstract][Full Text] [Related]
53. Synthetic vaccines: the role of adjuvants in immune targeting.
Jiang ZH; Koganty RR
Curr Med Chem; 2003 Aug; 10(15):1423-39. PubMed ID: 12871139
[TBL] [Abstract][Full Text] [Related]
54. MAVS Is Essential for Primary CD4
Luo H; Winkelmann E; Xie G; Fang R; Peng BH; Li L; Lazear HM; Paessler S; Diamond MS; Gale M; Barrett AD; Wang T
J Virol; 2017 Mar; 91(6):. PubMed ID: 28077630
[TBL] [Abstract][Full Text] [Related]
55. Carbohydrate-containing nanoparticles as vaccine adjuvants.
Zhang X; Zhang Z; Xia N; Zhao Q
Expert Rev Vaccines; 2021 Jul; 20(7):797-810. PubMed ID: 34101528
[No Abstract] [Full Text] [Related]
56. Monophosphoryl lipid A (MPL) as an adjuvant for anti-cancer vaccines: clinical results.
Cluff CW
Adv Exp Med Biol; 2010; 667():111-23. PubMed ID: 20665204
[TBL] [Abstract][Full Text] [Related]
57. Innate and adaptive immune correlates of vaccine and adjuvant-induced control of mucosal transmission of SIV in macaques.
Sui Y; Zhu Q; Gagnon S; Dzutsev A; Terabe M; Vaccari M; Venzon D; Klinman D; Strober W; Kelsall B; Franchini G; Belyakov IM; Berzofsky JA
Proc Natl Acad Sci U S A; 2010 May; 107(21):9843-8. PubMed ID: 20457926
[TBL] [Abstract][Full Text] [Related]
58. Pathogen-associated molecular patterns on biomaterials: a paradigm for engineering new vaccines.
Demento SL; Siefert AL; Bandyopadhyay A; Sharp FA; Fahmy TM
Trends Biotechnol; 2011 Jun; 29(6):294-306. PubMed ID: 21459467
[TBL] [Abstract][Full Text] [Related]
59. An inflammatory response is essential for the development of adaptive immunity-immunogenicity and immunotoxicity.
Nakayama T
Vaccine; 2016 Nov; 34(47):5815-5818. PubMed ID: 27745952
[TBL] [Abstract][Full Text] [Related]
60. The incidence and significance of pattern-recognition receptors in chronic viral hepatitis types B and C in man.
Mozer-Lisewska I; Sikora J; Kowala-Piaskowska A; Kaczmarek M; Dworacki G; Zeromski J
Arch Immunol Ther Exp (Warsz); 2010 Aug; 58(4):295-302. PubMed ID: 20533094
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
